Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$544.63 USD

544.63
358,441

-1.33 (-0.24%)

Updated Aug 26, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Stryker (SYK) Completes Artelon's Acquisition to Boost Business

by Zacks Equity Research

Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.

DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?

by Zacks Equity Research

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Here's Why Elevance Health (ELV) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Patterson Companies (PDCO) Aims to Streamline Patient Experience

by Zacks Equity Research

Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.

Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?

by Zacks Equity Research

Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.

3 Reasons Why You Should Hold McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson's (MCK) robust Biologics business raises optimism about the stock.

What Analyst Projections for Key Metrics Reveal About Elevance Health (ELV) Q2 Earnings

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

by Zacks Equity Research

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists

by Zacks Equity Research

Brookdale Senior's (BKD) weighted average occupancy for June rises 140 bps year over year.

Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Derek Lewis headshot

Tame Volatility with These 3 Low Beta Stocks

by Derek Lewis

Low beta stocks can offer stabilization when combined with high-beta stocks, providing a more balanced risk profile.

UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale

by Zacks Equity Research

By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.

Why Elevance Health (ELV) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Humana (HUM) Ties Up With PsychArmor for Better Veteran Care

by Zacks Equity Research

Humana's (HUM) subsidiaries team up with PsychArmor to enhance veteran care, offering specialized training at 23 senior primary care centers in Texas, thereby attracting more members of the targeted community to the centers.

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

by Zacks Equity Research

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection

by Zacks Equity Research

AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now

by Zacks Equity Research

Ecolab's (ECL) focus on research and development raises optimism about the stock

Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%

by Zacks Equity Research

AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.

Humana's (HUM) CenterWell Expands in Louisiana With New Centers

by Zacks Equity Research

Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.

Elevance Health (ELV) Rallies 11.8% YTD: More Room to Run?

by Zacks Equity Research

Elevance Health's (ELV) performance benefits from new contract wins, a strong Carelon segment and recovering Medicaid business.

Universal Health (UHS) Gains 28% in a Year: What Lies Ahead?

by Zacks Equity Research

Universal Health (UHS) remains well-poised for growth on the back of growing patient volumes, acquisitions and a commendable financial position.

Are Medical Stocks Lagging DURECT (DRRX) This Year?

by Zacks Equity Research

Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.